Streptococcus Pneumoniae Serotype 7F Conjugate Vaccine
This is a monovalent pneumococcal conjugate vaccine targeting Streptococcus pneumoniae serotype 7f. The vaccine works by linking the capsular polysaccharide of serotype 7f to the diphtheria CRM197 protein carrier, enhancing immune response particularly in infants and young children who respond poorly to polysaccharide antigens alone. It is designed to provide serotype-specific protection against pneumococcal disease caused by this particular serotype.
A conjugate vaccine providing targeted protection against Streptococcus pneumoniae serotype 7f using diphtheria CRM197 protein as an immune-enhancing carrier.
Key facts at a glance
- RxNorm
- 901636
- Generic
- Streptococcus Pneumoniae Serotype 7f Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Prevnar 20, Vaxneuvance, Capvaxive, Prevnar 13
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive pneumococcal disease, pneumonia, and otitis media caused by Streptococcus pneumoniae serotype 7f. Primarily used in pediatric populations as part of routine immunization programs or for high-risk individuals requiring serotype-specific protection.
The vaccine contains purified capsular polysaccharide antigen from S. pneumoniae serotype 7f, chemically conjugated to diphtheria CRM197 protein. This conjugation converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, producing stronger and more durable immune responses, particularly in infants and young children whose immune systems cannot effectively respond to polysaccharide antigens alone.
As a conjugate vaccine, it is contraindicated in individuals with known hypersensitivity to any vaccine component. Common adverse reactions include injection site reactions, fever, and irritability. Serotype 7f is included in most licensed pneumococcal conjugate vaccines (PCV13, PCV15, PCV20), so separate administration of this monovalent product is not typically required in routine practice. Vaccination schedules follow national immunization program recommendations.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 30, 2026. · Read our editorial policy